A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults with Psoriasis Vulgaris or Psoriatic Arthritis
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Si 544 (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Sponsors selectION
- 23 Jan 2025 Planned End Date changed from 31 Mar 2025 to 31 May 2025.
- 23 Jan 2025 Planned primary completion date changed from 31 Mar 2025 to 31 May 2025.
- 18 Oct 2024 Planned End Date changed from 30 Sep 2024 to 31 Mar 2025.